Lee Pharmaceuticals (LPHM) 0.0017 $LPHM 2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lee Pharmaceuticals (LPHM) 0.0017 $LPHM

2015 Investigation Report on China's Insulin Lispro Market 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
PR Newswire Europe - Thu Aug 06, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/963t94/investigation [http://www.researchandmarkets.com/research/963t94/investigation]) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" [http://www.researchandmarkets.com/research/963t94/investigation] report to their offering.
LLY: 82.09 (+0.11)

Research and Markets: Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
BusinessWire - Thu Aug 06, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8n6ks/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering.
LLY: 82.09 (+0.11)

Investigation Report on China's Insulin Lispro Market, 2010-2019 Featuring Eli Lilly and Company & Gan & Lee Pharmaceuticals
M2 - Thu Aug 06, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pbxrk/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development. There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million. For patients with type 1 diabetes mellitus, insulin is the only drug available. Besides, 30%-40% of type 2 diabetes will finally become insulin-dependent. Currently, the diabetic drug market at home and abroad both show rapid growth. Although international giants take up a large share, domestic enterprises are expected to break through in certain fields. The vast number of patients and demand for treatment will drive the diabetic drug market to expand. In recent years, insulin's share in the diabetic drug market has increasingly risen, 42% in the global market while nearly 40% in China. Insulin lispro is a fast-acting insulin analogue. Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, avoiding episodes of hypoglycemia. In the late 1990s, insulin lispro made by Eli Lilly and Company entered China. Later insulin lispro made by Gan & Lee Pharmaceuticals also came into the market. After entering China, insulin lispro develops fast with annual sales rising from less than CNY 7 million in 2005 to CNY 142 million in 2014 and CAGR during 2005-2014 reaching up to 40.1%. Currently, insulin lispro in the Chinese market mainly come from Eli Lilly and Company and Gan & Lee Pharmaceuticals. According to this market survey, Eli Lilly and Company has a larger market share of over 99% in 2014 by sales value. Key Topics Covered: 1Related Concepts of Insulin Lispro 2 Market Profile of Insulin Lispro in China 3 Survey on Sales Value of Insulin Lispro in China, 2010-2014 4 Survey on Sales Volume of Insulin Lispro in China, 2010-2014 5 Survey on Market Share of Major Manufacturers of Insulin Lispro in China, 2010-2014 6 Survey on Market Share of Dosage Forms of Insulin Lispro in China, 2010-2014 7 Reference Price of Insulin Lispro in Chinese Hospitals in 2014 8 Major Manufacturers of Insulin Lispro in Chinese Market, 2010-2014 9 Market Outlook of Insulin Lispro in China, 2014-2018 Companies Mentioned - Eli Lilly and Company - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/8p...estigation
LLY: 82.09 (+0.11)

The Incidence of Diabetes inside China keeps Growing and the Market Size of Diabetes Drugs Has Expanded Each Year, Exceeding CNY 20 Billion in 2014
M2 - Thu Jun 11, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62kjcv/investigation) has announced the addition of the "Investigation Report on China's Insulin Glargine Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth rate of diabetes in China and other developing countries has put a heavy burden on their social and economic development. In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition. According to the author's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014- 2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in February 2015, the global market structure is estimated to change in the next few years. On September 9th 2014, Eli Lilly and Company and Boehringer- ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in the Chinese market, some local enterprises are also hastening the development of Lantus's generic drug. Companies Mentioned: - Gan & Lee Pharmaceuticals - Aventis Behring GmbH - Tonghua Dongbao Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/62...estigation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 82.09 (+0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading